FDA Approves Landmark Pancreatic Cancer Drug Rasonque

The U.S. Food and Drug Administration on Wednesday approved Rasonque (daraxonrasib), a groundbreaking first-in-class targeted therapy for metastatic pancreatic cancer that nearly doubled patient survival in clinical trials. The once-daily oral pill, developed by Redwood City, California-based Revolution Medicines, is the first treatment to target a genetic cause of pancreatic cancer — a disease long considered one of the most difficult to treat.

The approval was granted 6.5 months ahead of the FDA’s user fee deadline, reflecting the agency’s commitment to accelerating access to innovative cancer treatments. According to the FDA’s announcement, the drug is indicated for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

A Decades-Long Challenge

Pancreatic cancer is among the most deadly forms of cancer, largely because it is difficult to detect before it spreads to other organs. The American Cancer Society estimates about 67,000 new cases will be diagnosed in the United States in 2026, with more than 52,000 deaths. The five-year overall survival rate is just 13%, as AP News reported.

Pancreatic ductal adenocarcinoma (PDAC) is the most common form, accounting for 90-95% of cases. Despite representing roughly 3.2% of all cancer diagnoses, PDAC accounts for a disproportionately high share of cancer deaths due to late detection, aggressive disease course, and historically limited treatment options.

For decades, the RAS gene family — which regulates cell growth and is mutated in more than 90% of pancreatic cancer cases — was considered “undruggable” because its structure made it difficult for drugs to bind to the mutated proteins. Daraxonrasib breaks through this barrier using a novel “molecular glue” mechanism that targets multiple RAS variants in their active state, potentially benefiting the vast majority of pancreatic cancer patients regardless of which specific mutation they carry.

Unprecedented Clinical Results

The approval was supported by the Phase 3 RASolute 302 trial, which enrolled 500 patients with previously treated metastatic pancreatic cancer. Patients receiving daraxonrasib achieved a median overall survival of 13.2 months compared to 6.7 months for those on standard chemotherapy — nearly doubling survival time, with a 60% reduction in the risk of death.

“This drug showed unprecedented results in an area of high unmet need,” said Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions.”

The detailed results, presented at the American Society of Clinical Oncology annual meeting in May and published in the New England Journal of Medicine, showed that patients on daraxonrasib reported less pain and better quality of life. Many patients remained on the drug after data analysis, suggesting the survival gap may widen as researchers continue tracking outcomes.

Dr. Brian Wolpin of the Dana-Farber Cancer Institute, principal investigator of the trial, said the drug should become “a new standard of care” for previously treated metastatic pancreatic cancer, according to STAT News.

Expert Reactions

The approval has generated significant enthusiasm among oncologists who have long struggled with limited treatment options for this aggressive disease.

“It will be transformative in the way we treat pancreas cancer. It’s the biggest development we’ve had in pancreas cancer in decades,” said Dr. Andrew Ko of the University of California, San Francisco. “I’m so thankful for this as an advance for our patients.”

Dr. Rachna Shroff of the University of Arizona Cancer Center, who has treated pancreatic cancer for 16 years, described her emotional reaction to the trial results: “I actually started crying when first seeing the study results. Patients stayed on this treatment because it was providing durable and meaningful benefit to them.”

Dr. Niharika B. Mettu of Duke Health noted, “We haven’t had advances in metastatic pancreatic cancer like this for more than 15 years,” adding that “the vast majority of — if not all — people with pancreatic cancer have a chance of benefiting from the drug.” Duke Health has been at the forefront of treating patients with daraxonrasib through clinical trials and an expanded access program.

The Ben Sasse Connection

The drug gained significant public attention earlier this year when former Sen. Ben Sasse (R-Neb.) described on CBS’s “60 Minutes” how he had experienced less pain while taking daraxonrasib. Sasse, who was diagnosed with stage 4 pancreatic cancer in December 2025, became a public face for the drug’s promise. The surge in public interest led the FDA to allow expanded access before official approval, as AP News reported.

The FDA issued a “safe to proceed” letter in May 2026 allowing Revolution Medicines to initiate an expanded access treatment protocol, enabling patient access to the investigational drug prior to approval under applicable FDA regulations.

What’s Next

Beyond this approval, Revolution Medicines is conducting additional Phase 3 trials exploring daraxonrasib as a first-line treatment for metastatic pancreatic cancer, as an adjuvant therapy after surgery, and in non-small cell lung cancer. Researchers will also explore whether tumor shrinkage might allow more patients to qualify for potentially curative surgery.

Leerink analysts estimate daraxonrasib could achieve approximately $7.6 billion in peak global revenue. Other companies, including BridgeBio, Immuneering, and Adlai Nortye, are developing competing approaches targeting the same RAS pathway.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer,” said Acting FDA Commissioner Kyle Diamantas. “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.”

While daraxonrasib is not a cure, it represents a major milestone in the fight against one of cancer’s most formidable foes — and a validation of the decades-long scientific quest to drug the “undruggable” RAS protein. The most common side effects include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

As Dr. Zev Wainberg of UCLA, co-lead of the study, put it: “While not curing the cancer, it is a very large step forward.”